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Abstract
We hypothesized that the immunogenicity of live Salmonella enterica serovar Typhi vaccines expressing heterologous
antigens depends, at least in part, on its rpoS status. As part of our project to develop a recombinant attenuated S.
Typhi vaccine (RASTyV) to prevent pneumococcal diseases in infants and children, we constructed three RASTyV strains
synthesizing the Streptococcus pneumoniae surface protein PspA to test this hypothesis. Each vector strain carried ten
engineered mutations designed to optimize safety and immunogenicity. Two S. Typhi vector strains (x9639 and x9640)
were derived from the rpoS mutant strain Ty2 and one (x9633) from the RpoS
+ strain ISP1820. In x9640, the
nonfunctional rpoS gene was replaced with the functional rpoS gene from ISP1820. Plasmid pYA4088, encoding a
secreted form of PspA, was moved into the three vector strain s .T h er e s u l t i n gR A S T y Vs t r a i n sw e r ee v a l u a t e df o rs a f e t y
in vitro and for immunogenicity in mice. All three RASTyV strains were similar to the live attenuated typhoid vaccine
Ty21a in their ability to survive in human blood and human monocytes. They were more sensitive to complement and
were less able to survive and persist in sewage and surface water than their wild-type counterparts. Adult mice
intranasally immunized with any of the RASTyV strains developed immune responses against PspA and Salmonella
antigens. The RpoS
+ vaccines induced a balanced Th1/Th2 immune response while the RpoS
2 strain x9639(pYA4088)
induced a strong Th2 immune response. Immunization with any RASTyV provided protection against S. pneumoniae
challenge; the RpoS
+ strain x9640(pYA4088) provided significantly greater protection than the ISP1820 derivative,
x9633(pYA4088). In the pre-clinical setting, these strains exhibited a desirable balance between safety and
immunogenicity and are currently being evaluated in a Phase 1 clinical trial to determine which of the three RASTyVs
has the optimal safety and immunogenicity profile in human hosts.
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Introduction
Vaccines based upon live, attenuated pathogens were originally
developed to prevent infection by homologous pathogens. The
success of these vaccines ((BCG, oral polio (Sabin), MMR and
Ty21a)) raised the possibility that a live, attenuated pathogen
could be used to stimulate immunity not only against itself, but
also heterologous pathogens by expressing foreign antigens. This
idea is particularly attractive for pathogens that require a complex
or mucosal immune response for protection, since other
vaccination strategies are not as effective at stimulating these
kinds of immune responses. The success of the chemically
attenuated S. Typhi Ty21a vaccine [1] indicated the feasibility
of developing rationally attenuated, highly immunogenic live S.
Typhi vaccines.
Early success with live attenuated homologous bacterial
vaccines led to the development of strategies to modify the
vaccine strains for use as vectors to deliver a variety of protective
antigens via the mucosal route. This is particularly advantageous
for pneumococcal protein antigens as delivery via the mucosal
route elicits secretory as well as serum antibody responses,
resulting in protection against carriage as well as systemic disease
[2,3,4]. Recombinant attenuated Salmonella enterica serovar Typhi-
murium vaccines (RASVs) expressing the pneumococcal antigen
gene pspA have been constructed and demonstrated to induce
protective immunity in mice against challenge with virulent S.
pneumoniae [5,6]. Translating what works in S. Typhimurium for
mice into a S. Typhi-based vaccine for humans has led to mixed
results. Although DgalE [7], DaroC, DaroD [8], Dcya Dcrp [9] and
DphoPQ [10,11] mutants of S. Typhimurium were completely
attenuated in mice and induced protective immunity to challenge
with wild-type S. Typhimurium, S. Typhi DgalE [12], DaroC DaroD
and Dcya Dcrp [13] mutants were not adequately attenuated and
caused significant reactogenicity in humans. It thus became
necessary to devise new strategies to overcome reactogenicity
issues. For example, the strains such as (Dcya Dcrp-cdt) [14,15],
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11142CVD908-htrA [16] and an DaroC DssaV S. Typhi Ty2 [17] are
reported to be safe and immunogenic in humans. However, a phoP
mutant of S. Typhimurium, completely attenuated in mice [10],
led to development of a safe and immunogenic DphoPQ S. Typhi
vaccine strain [18].
Although RASVs have been successfully used to express
recombinant antigens and induce protective immunity in animals
[19], recombinant attenuated S. Typhi vaccines (RASTyV;
vaccine strains synthesizing heterologous antigens) have not been
sufficiently effective in human studies to justify commercial
development [20]. There are several reasons for the lack of
success using live S. Typhi vectors in humans. The major difficulty
has been in establishing a balance between eliciting a strong
immune response to the vectored antigen and reactogenicity. Non-
reactogenic strains are often hyperattenuated and induce poor
immune responses, even to Salmonella antigens [14,18]. It is likely
that the recombinant S. Typhi strains do not colonize lymphoid
tissues such as the gut-associated lymphoreticular tissues (GALT),
mesenteric lymph nodes and spleen to a sufficient level to stimulate
a robust immune response against the foreign antigen. The host
immune system may also be ‘‘distracted’’ by the Salmonella carrier,
mounting a strong response against Salmonella antigens instead of
the vectored antigen.
Recently, we have begun to understand another possible
reason for the poor results with live RASTyV strains expressing
protective antigens from a diversity of pathogens. It was
reported that rpoS mutations attenuate S. Typhimurium [21]
and this led shortly thereafter to the demonstrated role of RpoS
in regulating genes on the S. Typhimurium virulence plasmid
[22,23]. S. Typhimurium strains with rpoS mutations have
markedly diminished abilities to colonize the Peyer’s patches in
mice [24]. Virulence plasmid-cured S. Typhimurium strains
colonize Peyer’s patches as well as wild-type strains [25],
indicating that chromosomal genes controlled by rpoS must be of
critical importance for Peyer’s patch colonization. We thus
theorized that rpoS mutations not only attenuate Salmonella but
also likely lessen their immunogenicity. This fits with past
experiences when it was reported that S. Typhi Ty2, which had
been used by most groups constructing RASTyV strains to
evaluate in humans, was an rpoS mutant [26]. When adminis-
tered at high doses, S.T y p h i m u r i u mrpoS mutants can protect
against homologous, but not heterologous challenge [26,27]. In
our own unpublished studies, we examined the immunogenicity
of rpoS m u t a n t s .I nad o s er e s p o n s es t u d y ,w ef o u n dt h a t
introduction of an DrpoS mutation reduces the protective
efficacy of a live S. Typhimurium strain (unpublished results).
Introduction of a regulated rpoS expression cassette [28] into a
recombinant attenuated S. Typhimurium vaccine strain results
in a substantial reduction in the immune response directed
against the vectored antigen (unpublished results). Therefore,
we postulated that an RpoS
+ S. Typhi RASV strain would be
more effective at inducing protective immune responses to
recombinant antigens than an RpoS
2 S.T y p h i( e . g .T y 2 )
vaccine strain.
Based on our current knowledge about the RpoS phenotypes of
S. Typhi strains, it can be inferred that attenuated RpoS
+ S. Typhi
strains are more virulent in humans than equivalent RpoS
2 S.
Typhi strains with the same attenuating mutations [13]. Use of
RpoS
+ S. Typhi antigen delivery vectors will therefore necessitate
degrees of attenuation in excess of what is necessary to attenuate S.
Typhi Ty2 strains for humans, but these means of attenuation
must not compromise immunogenicity.
S. Typhimurium infection in mice is often used as a model of
typhoid fever, due to the host-restriction of S.T y p h ia n dt h e
absence of a small animal model to evaluate typhoid fever
caused by S. Typhi. We have recently developed a number of
new systems in S. Typhimurium designed to enhance the safety
and immunogenicity of RASVs, including regulated delayed in
vivo attenuation [28,29], regulated delayed antigen synthesis
[30] and regulated cell lysis [31]. We have also modified
antigen, repressor and plasmid vector sequences to enhance
transcription and translation efficiencies to maximize protective
antigen synthesis in vivo. In addition, we have also explored
other means to enhance immunogenicity and safety, including
the DsopB mutation, which reduces Salmonella-induced fluid
secretion in the intestines [32,33,34] and enhances the
immunogenicity of a vectored antigen [35]. Many of these
features were combined to create S. Typhimurium strain x9558
[34]. In addition, this strain also has a DasdA mutation, allowing
use of the antibiotic resistance-free Asd
+ balanced-lethal plasmid
maintenance system [36]. When complemented with an Asd
+
plasmid that directs expression of the pneumococcal gene pspA,
x9558 has been shown to be safe, immunogenic and capable of
eliciting an immune response that protects against challenge
with virulent Streptococcus pneumoniae, in both adult [37,38] and
infant [34,39] mice.
S. pneumoniae is a formidable bacterial pathogen, causing
disease with high morbidity and mortality even in regions where
antibiotics are readily available. S. pneumoniae is estimated to kill
1–2 million children under the age of 5 years each year in
developing countries, accounting for 20–25% of all deaths in
this age group [40]. Antibodiest op n e u m o c o c c a lc a p s u l a r
polysaccharides can protect against fatal infection, but this
protection is serotype specific. Current vaccines based on
capsule polysaccharides therefore provide coverage only for
the specific serotypes included in the vaccine. There are 91
distinct capsular serotypes of S. pneumoniae [41,42], and
geographic differences in serotype prevalence have resulted in
suboptimal protection in many countries. Recent reports have
shown that although carriage of vaccine serotypes was reduced
in immunized individuals, the vacated niche was promptly
occupied by non-vaccine serotypes [43,44,45]. This ‘‘replace-
ment carriage’’ has translated into a significant increase in cases
of invasive disease caused by non-vaccine serotypes in conjugate
vaccine recipients [46]. Because of these concerns, we focused
our attention on developing a vaccine based on pneumococcal
proteins, such as PspA, that contribute to virulence and are
common to all serotypes [47].
In this work, we constructed three new recombinant
attenuated S. Typhi vaccines (RASTyV) derived from S.T y p h i
Ty2, its RpoS
+ derivative [48] and ISP1820 expressing pspA
from an Asd
+ expression plasmid. We introduced a constellation
of mutations nearly identical to those present in S.T y p h i m u r -
ium strain x9558 [34,38]. In particular, two mutations, Dpmi
and DtviABCDE, affecting synthesis of two major S.T y p h i
surface antigens, O-antigen and Vi capsule, respectively, were
included in an attempt to reduce the host immune response to
Salmonella,a n d ,h o p e f u l l y ,t oe n h a n c et h ei m m u n er e s p o n s et o
the vectored antigen, PspA. We evaluated each strain for safety,
persistence in the environment and in human blood and
immunogenicity in mice.
Materials and Methods
Ethics statement
All research involving human participants was conducted as
per Protocol #0804002872, approved by the Arizona State
University Institutional Review Board. Informed consent was
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Strains Genotype or relevant characteristics Source or derivation
E. coli
x7213 thr-1 leuB6 fhuA21 lacY1 glnV44 recA1 DasdA4
D(zhf-2::Tn10) thi-1 RP4-2-Tc :: Mu [l pir]; Km
r
[96]
Salmonella enterica Typhimurium
x3761 UK-1 wild type [97]
x8477 DaraE25 [28]
x8606 DagfBAC811 [34]
x8650 Dpmi-2426 [29]
x8767 DaraBAD23 [28]
x8831 D(gmd-fcl)-26 [28]
x9277 DsopB1925 [35]
x9021 DPcrp527 :: TT araC PBAD crp [28]
x9034 DPphoPQ107 :: TT araC PBAD phoPQ [28]
x9226 DrelA198 :: araC PBAD lacI TT [98]
x8848 DPfur33 :: TT araC PBAD fur [28]
x9269 DPfur81 :: TT araC PBAD fur [28]
x8958 DasdA33 UK-1
S. Typhi Ty2
Ty2 RpoS
2 [99]
Ty21a Ty2, galE ilvD viaB, phenotypically H2S
2 ATCC 3345
x8438 Ty2 RpoS
+ [48]
x9043 DPcrp527:: TT araC PBAD crp Ty2
x9205 DPfur33:: TT araC PBAD fur x9043
x9213 DPphoPQ107:: TT araC PBAD phoPQ x9205
x9288 Dpmi-2426 x9213
x9335 D(gmd-fcl)-26 x9288
x9369 DrelA198:: araC PBAD lacI TT x9335
x9416 DaraE25 x9369
x9478 DtviABCDE10 x9416
x9511 DagfBAC811 x9478
x9580 DsopB::Cm-SacB x9511
x9584 DsopB1925 x9580
x9601 DPfur81:: TT araC PBAD fur x9584
x9603 PphoP+ x9601
x9639 Dasd33 x9603
x9640 RpoS+ x9639
S. Typhi ISP1820
ISP1820 Wild-type [100]
x9044 DPcrp527:: TT araC PBAD crp ISP1820
x9142 DPfur33::TT araC PBADfur x9044
x9196 DPphoPQ107:: TT araC PBAD phoPQ x9142
x9211 Dpmi-2426 x9196
x9214 D(gmd-fcl)-26 x9211
x9298 DsopB1925 x9214
x9327 DrelA198:: araC PBAD lacI TT x9298
x9342 DaraE25 x9327
x9364 DaraBAD23 x9342
x9365 DtviABCDE10 x9364
x9419 DagfBAC811 x9365
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tion of Helsinki. The Arizona State University Institutional
Animal Care and Use Committee approved all animal
procedures.
Strains, plasmids and culture conditions
The strains used in this study are described in Table 1. S. Typhi
strains Ty2 and Ty21a were kind gifts from Lou Baron at
WRAIR. Asd
+ plasmids and suicide plasmids are listed in Table 2.
Cultures were routinely grown at 37uC in LB broth [49] or LB
agar. Strains were stored in either peptone-glycerol or animal-free
phytone-glycerol (1% peptone or phytone (Difco, Detroit, MI,
USA) and 5% glycerol (Fisher Scientific Inc., Pittsburgh, PA,
USA). Nutrient broth (NB) and agar (Difco), MacConkey agar
(Difco), 3XD plates [50] supplemented with 50 mg/ml of 5-bromo-
4-chloro-3-indolyl-phosphate (Roche, Indianapolis, IN, USA),
Kornberg agar [51], chrome azurol S (CAS) plates [52], and
yeast congo-red agar [53], were used for routine phenotype
corroboration. When required, media were supplemented with
chloramphenicol (Cm; 25mg/ml), tetracycline (Tet; 12.5 mg/ml), 2,
6-diaminopimelic acid (DAP; 50 mg/ml), L-arabinose (0.05% or
0.2% wt/vol), D-mannose (0.2% wt/vol), D-lactose (1% wt/vol),
D-maltose (1% wt/vol), sucrose (5% wt/vol), L-cysteine-HCl
(22 mg/ml), or L-tryptophan (20 mg/ml). Tetrathionate broth
(Difco), with or without supplements, was used for enrichment of
S. Typhi from animal tissues. Bacterial growth was monitored
spectrophotometrically and by direct plating for colony counts.
KT broth is a proprietary animal-free complex medium, similar to
terrific broth [54], used for rapid and high-density growth of S.
Typhi vaccine strains. Cultures maintained under different
environmental stresses were plated on MacConkey agar (Difco),
and then patched onto XLT-4 agar (Difco) and Bismuth sulfite
agar (Difco). Oligonucleotides were from IDT (Coralville, IA,
USA) (Table 3). Restriction endonucleases were from New
England Biolabs, (Ipswich, MA, USA). Taq DNA polymerase
(New England Biolabs) was used in all PCR tests. Qiagen products
(Hilden, Germany) were used to isolate plasmid DNA, gel-purify
fragments or purify PCR products. T4 ligase, T4 DNA polymerase
and shrimp alkaline phosphatase (SAP) were from Promega
(Madison, WI, USA).
Strains Genotype or relevant characteristics Source or derivation
x9421 DPfur81:: TT araC PBAD fur x9419
x9599 PhoP+ x9421
x9633 DasdA33 x9599
doi:10.1371/journal.pone.0011142.t001
Table 1. Cont.
Table 2. Plasmids used in this study.
Plasmids Relevant characteristics Source or derivation
pDMS197 5,612 bp, Tet sacB oriV oriT [101]
pMEG375 8,142 bp, Cm, Amp, lacZ,R 6 Kori, mob incP, sacR sacB [102]
pRE112 5,173 bp, Cm, sacB oriV oriT [101]
pYA3433 Wild-type rpoS allele from S. Typhi ISP1820, pMEG-375 [48]
pYA3484 DaraBAD23, pMEG-375 [28]
pYA3485 DaraE25, pMEG-375 [28]
pYA3493 Plasmid Asd
+; pBR ori b-lactamase signal sequence-based
periplasmic secretion plasmid
[29]
pYA3492 DagfBAC811, pDMS197 [103]
pYA3546 Dpmi-2426, pDMS197 [29]
pYA3629 D(gmd-fcl)-26, pMEG-375 [29]
pYA3722 DPfur33::TT araC PBAD fur, pMEG-375 [28]
pYA3723 DPphoPQ107::TT araC PBAD phoPQ, pRE112 [28]
pYA3733 DsopB1925, pMEG-375 [35]
pYA3736 DasdA33, pRE112 This study
pYA3832 DPcrp527::TT araC PBAD crp, pRE112 [28]
pYA3879 DrelA198::TT araC PBAD lacI, pRE112 Lab collection
pYA4009 DtviABCDE10, pRE112 [48]
pYA4088 852-bp DNA encoding the a-helical region of PspA aa 3–285 in pYA3493 [30]
pYA4181 DPfur81::TT araC PBAD fur, pMEG-375 [28]
pYA4491 DTT araC PBAD::PphoP, pRE112 This study
doi:10.1371/journal.pone.0011142.t002
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11142Construction of S. Typhi strains with defined unmarked
chromosomal insertion/deletions
We used several means to generate defined deletion and
deletion-insertion mutations leaving behind no DNA scars or
antibiotic-resistance markers by using suicide plasmid-based
technologies [55,56] and a two-step recombination method [57].
In all cases, we determined the DNA sequence of the flanking
regions used to construct chromosomal mutations. We made
insertions of araC PBAD into the chromosome by cloning araC PBAD
between DNA regions flanking the desired insertion point [28].
The araC PBAD cassette we used includes transcription terminator
(TT) sequences to preclude araC transcription reading into
adjacent genes and interfering with their function [28]. By the
same logic, a TT sequence was included downstream of lacI in the
DrelA198 deletion/insertion. We used these methods to generate
most of the deletion/insertions in S. Typhimurium. Mutations
were moved from S. Typhimurium (Fig. 1) into S. Typhi strains by
P22HTint transduction [58]. Suicide vectors were used to
introduce some mutations into Salmonella strains by conjugation
with E. coli x7213 [48].
Characterization of S. Typhi strains in vitro
All the S. Typhi constructions were characterized for type I
fimbriae production in static LB broth cultures [59] by yeast
agglutination [60] and for motility in motility medium (bioMe ´riux,
Marcy I’Etoile, France). Lipopolysaccharide (LPS) profile was
evaluated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis then visualized by silver staining [61]. Plasmid profiles
were verified by alkaline lysis and agarose gel (0.5%) electropho-
resis [62]. Biochemical profiles were determined in the presence
and absence of 0.2% arabinose using the API 20E system
(bioMe ´riux). The presence of Vi, O and flagella antigens were
evaluated by agglutination assays. The presence or absence of
RpoS was determined by addition of hydrogen peroxide to
cultures to detect activity of the RpoS-dependent catalase, KatE
[63,64], and by glycogen accumulation when streaked on
Kornberg glycogen indicator agar [65]. The presence of each
chromosomal mutation was verified by PCR using the appropriate
DNA primers (Table 3). Stability of Asd
+ plasmids in vaccine
strains was determined as described [66].
SDS-PAGE and immunoblot analyses
To evaluate arabinose dependent regulation of gene expression,
strains were grown in NB medium with 0.05% arabinose at 37uC
with aeration. When the culture reached an OD600nm of 0.8, it was
diluted 1:10 into fresh NB without arabinose and grown to an
OD600 of 0.8. This process was repeated 6 times (,20
generations). One ml of culture was collected from each passage
and prepared for western blot analysis [54]. Total protein was
normalized, samples were separated on a 10% (wt/vol) sodium
dodecyl sulfate-polyacrylamide gel and transferred onto nitrocel-
lulose membranes. Fat-free milk powder dissolved in phosphate
buffered saline (PBS) (5%, wt/vol) supplemented with 0.05%
Tween 20 (PBS-T) was used for blocking. The membrane was
incubated with an appropriate anti-rabbit polyclonal antibody
(1:10,000), anti-Fur, anti-Crp, and anti-LacI [28], anti-PspA [30],
anti-GroEL (Sigma, St. Louis, MO, USA) or anti-mouse
monoclonal antibody (1:1,000) anti-RpoD (Neoclone, Madison,
WI, USA) for 1 h at room temperature, washed three times with
PBS-T, and then incubated with a 1:10,000 dilution of alkaline
phosphatase-conjugated anti-rabbit immunoglobulin G (IgG)
Table 3. Oligonucleotides used to verify the genotype of the RASTyV strains. F: forward primer; R: reverse primer.
Deletion/insertion Oligonucleotides
DaraBAD1923 F5 9-ACATGCATGCGGACGATCGATAA
R5 9-CGGGATCCTGGTAGGGAACGAC
DaraE25 F5 9-GACTGCATGCATGGTGTTGGTACA
R5 9-CGGGATCCCATAGCGGTAGATG
DagfBAC811 F5 9-GCACTGCTGTGGGTTGAAATAG
R5 9-CGGCGTGAGTAGAAATATCG
Dpmi-2426 F5 9-GGGGGTACCTTCGGCGACGGAAACATGTTCGCT
R5 9-GGGGGCTCGCCGCGCTGGTAGTTTTGATAACTTAA
D(gmd-fcl)-26 F5 9-TCCCCCGGGCAAAATATTGTATCGCTGG
R5 9-GCACGCATGCTCAGGCAGGCGTAAATCGCTCT
DPfur33::TT araC PBAD fur
DPfur81::TT araC PBAD fur
F5 9-ACATGCATGCTGTGACTGGGATGACTTCTTCCCG
R5 9-TCCCCCGGGCACTTTTCCGCAATCAAGGCAG
DPphoPQ107::TT araC PBAD phoPQ F5 9-TGCGAGCTCCGATGTGGAATGGCTTCGTCAC
F5 9-ACATGCATGCGCAAACAAACTGCCGGTTTCCCCGC
DsopB1925/sigD F5 9-ACATGCATGCGGCATACACACACCTGTATAACA
R5 9-TTCCCCCGGGGCAGTATTGTCTGCGTCAGCG
DasdA33 F5 9-TGCTCTAGATGTGCATGGCAATCGCCCAAC
R5 9-TCCCCCGGGTATCTGCGTCGTCCTACCTTC
DPcrp527::TT araC PBAD crp F5 9-ACATGCATGCATCTCCATCGGACTCGGCGCTTT
R5 9-TGCGAGCTCCAGAATATCCGGGTTGACCTG
DrelA::TT araC PBAD lacI F5 9-CCCAAGCTTGAGCTCGAGGGCGTTCCGGCGCTGGTAGAA
R5 9-CGGGTACCCCAGATATTTTCCAGATCTTCAC
DtviABCDE10 F5 9-ACATGCATGCGAACGGTATTACTGTCAGTCACAAG
R5 9-TCCCCCGGGCAGATTATTTCAAATACGATTAGG
DTT araC PBAD::PphoP F5 9-TGCGAGCTCCGATGTGGAATGGCTTCGTCAC
F5 9-ACATGCATGCGCAAACAAACTGCCGGTTTCCCCGC
doi:10.1371/journal.pone.0011142.t003
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x9633, x9639 and x9640. Beginning at the top of the figure with parent strains ISP1820 and Ty2, individual mutations or other genetic modifications
were introduced using suicide plasmids introduced either by conjugation or transduction. In one case, the mutation was introduced using the l red
method.
doi:10.1371/journal.pone.0011142.g001
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nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate
(BCIP) (Sigma).
Salmonella subcellular fractionation
Cultures were grown in NB to an OD600 of 0.6 and centrifuged
at 5,8006g for 10 min. Periplasmic fractions were prepared by a
modification of the lysozyme-osmotic shock method [67] as
previously described [6]. The supernatant fluid was saved for
analysis of secreted proteins. Equal volumes of outer membrane
proteins (OMPs), periplasmic, cytoplasmic, and supernatant
fractions and total lysate samples were separated by SDS-PAGE
for western blot analysis.
Deoxycholate sensitivity assay
RASTyV strains and wild-type Salmonella Typhi strains were
grown in KT broth to a cell density of approximately 1610
9
CFU/ml (late log phase). The growth media for the RASTyV
strains were supplemented with 0.2% arabinose and 0.2%
mannose. Cultures were harvested by centrifugation at 25006g
for 20 min at room temperature. Cells were resuspended in PBS
and allowed to acclimate for one hour. Following acclimation, the
cells were pelleted and the PBS was removed. Cells were
transiently exposed to sodium deoxycholate in PBS (0, 0.1, 0.25,
0.5, 1.0, 2.5 and 5.0%) for 2 h at 37uC (final concentration 1610
9
CFU). The number of viable cells after deoxycholate treatment
was assessed by duplicate plating on LB agar+0.2% arabinose.
This experiment was repeated three times.
Survival of Salmonella strains in chlorinated water,
surface water and in raw sewage
Chlorinated water was prepared by dissolving a crushed
chlorine pool tablet into distilled water to a final concentration
of 4,5 ppm (chlorine concentration was determined by the
SenSafe chlorine testing kit (Industrial Test Systems, Rock Hill,
SC, USA)). Chlorinated water was used within 10 min of
preparation. Frozen stocks were thawed at 37uC, and then
residual phytone-glycerol was removed by washing cells with PBS.
Cells were suspended in 1 ml of PBS to a concentration of
160.2610
9 CFU/ml. The actual titer was measured by plating
serial dilutions onto LB agar+0.2% arabinose. 1610
9 CFU of cells
were diluted into 19 ml of chlorinated water, and viability was
assessed by plating at 10, 30 and 60 min after the addition of
chlorine. Samples were prepared in triplicate and plated in
duplicate at all time points.
Raw sewage samples were obtained from the Kyrene Water
Reclamation Facility in Tempe, AZ and were used within one
week of collection. Untreated surface water samples were
obtained from Tempe Canal in Tempe, AZ and were used
within one week of collection. The sewage was diluted 1:1000 in
PBS prior to use to reduce the number of background organisms
to ,1610
5 CFU/ml. S. Typhi wild-type and RASTyV strains
from phytone-glycerol frozen stocks were thawed, and the cells
washed with PBS, then inoculated into triplicate 20 ml surface
water or sewage samples to a concentration of 1610
8 CFU/ml.
Samples were incubated at ambient temperature (21–25uC) for
the duration of the assay. Viability of the Salmonella strains was
assessed on days 0, 1, 3, 7 and 10 after inoculation by plating on
MacConkey agar+1% lactose and % mannose. For untreated
surface water cultures containing wild-type ISP1820 or
x9633(pYA4088), brilliant green agar (Difco) containing 0.2%
arabinose and 0.2% mannose was used in place of MacConkey
agar. Each sample was plated in duplicate for each time point.
Plates were compared to pure cultures streaked on identical
media. All colonies suspected to be Salmonella were patched onto
Bismuth-sulfite, XLT-4 and MacConkey agar+1.0% maltose+/
20.2% arabinose for verification. The limit of detection for this
assay was 1610
4 CFU/ml.
Human Subjects
Individuals who had received a vaccine directed against S.
Typhi were excluded from participating in the study. Up to 50 ml
of blood was collected from individual volunteers by venipuncture
and treated with sodium heparin to prevent coagulation [68].
Samples were used as whole blood or processed to isolate
monocytes within 24 h of collection.
Survival of Salmonella strains in whole human blood and
in human peripheral monocytes
RASTyV strains containing pYA4088, wild-type Salmonella
Typhi strains and Ty21a were grown in KT broth to a cell
density of approximately 1610
9 CFU/ml (late log phase). The
growth media for the vaccine strains were supplemented with
0.2% arabinose and 0.2% mannose. Ty21a was grown in the
presence of 0.05% galactose (this concentration was found to allow
complete LPS O-antigen synthesis without reducing the strain
growth rate). In some experiments, blood components were
inactivated by incubation at 55uC for one hour. For survival of
Salmonella strains in whole human blood, cells were diluted in
phosphate buffered saline (PBS), pH 7.4 and inoculated into
untreated or heat-inactivated fresh human blood to a density of
approximately 1610
6 CFU/ml. Inoculated samples and uninoc-
ulated controls were incubated at 37uC for the duration of the
assay. Bacterial viability was assessed by plating onto LB agar with
0.2% arabinose at 0, 3, 6 and 18 h after inoculation. The assay
was performed in duplicate and was repeated 3 times using blood
samples from different individuals. The limit of detection for this
assay was less than 10 CFU/ml.
For intracellular survival of Salmonella in human peripheral
monocytes, peripheral blood monocytes were isolated from human
blood by Ficoll-Paque PLUS (GE Healthcare) gradient [69].
Monocytes were washed with Hank’s buffered salts solution
(Invitrogen, Carlsbad, CA, USA), resuspended in RPMI 1640
(Invitrogen) without serum at a concentration of approximately
5610
5 cells/ml and allowed to adhere to Corning Costar 24-well
plates for 1 h at 37uC, 5.0% CO2. Non-adherent cells were
removed after 1 h by washing with PBS and RPMI 1640 without
serum was added to the monolayer. The bacterial invasion assay
was carried out essentially as described [70]. Salmonella strains were
suspended in RPMI 1640 at a concentration of approximately
5610
6 CFU/ml and allowed to invade the human monocytes for
1 h at 37uCi n5 %C O 2 (MOI of 10:1). After one hour, cells were
treated with 100 mg/ml gentamicin to kill extracellular bacteria.
The number of intracellular bacteria was assessed at 1, 4 and 24 h
after inoculation. Monocytes were lysed with 0.1% sodium
deoxycholate for 5 min and samples were serially diluted in PBS
and plated on LB agar+0.2% arabinose. This assay was performed
in duplicate and was repeated three times using cells isolated from
different individuals.
Sensitivity of RASTyV strains to guinea pig serum
complement
The complement sensitivity assay was carried out essentially
as described [71]. Briefly, RASTyV strains with pYA4088 and
wild-type Salmonella Typhi strains were grown in KT broth to a
cell density of approximately 1610
9 CFU/ml (late log phase).
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0.2% arabinose and 0.2% mannose. Cells were diluted to
approximately 1610
6 CFU/ml in PBS and were exposed to
22% purified guinea pig complement in PBS (Calbiochem, San
Diego, CA, USA) in the presence or absence of Group D1 LPS
O-antigen antibody (BD Bioscience, Franklin Lakes, NJ, USA).
Reactions were incubated 3 h at 37uC. Complement-resistant
cells were enumerated by plating on LB agar+0.2% arabinose.
The assay was conducted in duplicate, and was repeated a
minimum of 3 times for each strain.
Mice
Female and male BALB/c mice, 6 to 7 weeks old, were
obtained from the Charles River Laboratories. Mice were
acclimated for 7 days after arrival before starting the
experiments. Newborn mice (less than 24 hours old) were
obtained from pair-wise mating of female and male BALB/c
mice.
Distribution of Salmonella bacteria in newborn mice
Groups of newborn mice were orally inoculated with 10 ml
containing 1610
9 CFU of Salmonella vaccine strains, wild-type
strains, or Ty21a. Mice were euthanized and necropsied at various
times. Spleen, liver, and whole intestines were collected on days 3
and 7 post-infection. Tissues were weighed and homogenized in a
final volume of 1 ml buffered saline with gelatin (BSG) [72] and
serial dilutions plated onto MacConkey agar plates containing 1%
lactose, and with or without 0.05% arabinose and 0.2% mannose
to determine the number of viable bacteria. Plates were incubated
at 37uC for at least 18 h. We also used 900 ml of homogenized
tissues to inoculate 5 ml tetrathionate broth (Difco) for Salmonella
enrichment. Samples that were negative by direct plating and
positive by enrichment were recorded as 10 CFU/g. Samples that
were negative by both direct plating and enrichment were
recorded as 0 CFU/g.
Immunization of mice
RASTyV vector strains harboring plasmids pYA4088 (pspA)o r
pYA3493 (empty vector) were grown in LB broth with 0.05%
arabinose and 0.2% mannose overnight at 37uC as standing
cultures that were diluted 1:100 in the same medium, prewarmed,
and grown with aeration (180 rpm) at 37uCt oa nO D 600 of 0.8 to
0.9. Bacteria were collected by centrifugation at room temperature
and resuspended in BSG to densities appropriate for the
inoculation route and dose. To determine the actual CFU/dose,
serial dilutions of the RASTyV strains were plated onto
MacConkey agar supplemented with 1% lactose, with or without
0.05% arabinose and 0.2% mannose. Seven-week-old mice were
inoculated intranasally with 160.2610
9 CFU of RASTyV vector
strains carrying either the pspA expression plasmid pYA4088 or
control plasmid pYA3493 in 10 ml. Mice were boosted with the
same dose of the same strain six weeks later. Blood was obtained
by mandibular vein puncture at biweekly intervals. Blood was
incubated at 37uC for 60 min and the clot was pelleted by
centrifugation. Serum was removed from the whole-blood samples
and stored at 220uC. Vaginal-wash samples were collected at
biweekly intervals and stored at 220uC as described [6]. Sera were
collected 2, 4, 6 and 8 weeks after the initial vaccination and serum
IgG responses to rPspA, S. Typhi LPS and S. Typhi OMPs were
measured. This experiment was performed twice, with each group
(8 mice) receiving approximately the same dose of vaccine, and the
results from both experiments were similar and have been pooled
for analysis.
Antigen preparation
PspA protein was purified as described previously [6]. S. Typhi
LPS was obtained from Sigma. Serovar Typhi outer membrane
proteins (SOMPs) were purified from S. Typhi strain x9633 as
described previously [6]. The PspA-Rx1 clone was a kind gift from
Susan Hollingshead at the University of Alabama at Birmingham.
Enzyme-linked Immunosorbent Assay (ELISA)
Sera from all mice in a group were pooled for analysis. ELISA
was used to measure IgG antibodies against S. Typhi LPS, SOMPs
and rPspA in serum, IgG1 and IgG2a in serum and IgA in vaginal
washes against rPspA as previously described [6,38]. Absorbance
was recorded at 405 nm using an automated ELISA plate reader
(model EL311SX; Biotek, Winooski, VT). Absorbance readings
that were 0.1 higher than BSG control values were considered
positive [38].
IL-4 and IFN-c ELISPOT assays
At week 7, spleen cells were harvested from 3 mice per group.
Cells from each spleen were assayed by ELISPOT in triplicate
wells as previously described [73]. Briefly, PVDF membrane plates
(Millipore) were washed with sterile H2O, and coated with 100 ml
of anti-IL-4 or anti-IFN-c mAbs (BD PharMingen, San Jose, CA,
USA) at 5 mg/ml in PBS overnight at 4uC. The wells were washed
with PBS and blocked with RPMI containing 10% FCS. Then,
50 ml of cell medium (RPMI-1640 supplemented with 10% FCS,
2 mM L-glutamine, 100 IU/ml penicillin, and streptomycin and
1% HEPES) and 50 ml of spleen cells (10
6 per well) in cell medium
with or without stimulation with rPspA at 5 mg/ml were added per
well and incubated in the plates overnight in 5% CO2 at 37uC.
The next day, the cell suspensions were discarded and the plates
washed with PBS-T. Biotinylated anti-IL-4 or anti-IFN-c mAb
(BD PharMingen) at 5mg/ml in PBS-T with 1% FCS was added
and incubated at room temperature for 2 h. After washing with
PBS-T, 100 ml/well of avidin peroxidase diluted 1:1,000 (vol/vol)
in PBS-T containing 1% FCS were added, followed by incubation
for 1 h at room temperature. After washing with PBS-T, 100 mlo f
AEC (3-amino-9-ethylcarbazole, BD Bioscience) was added per
well. Spots were developed for 15 min at room temperature. Plates
were dried and analyzed by using an automated CTL ELISPOT
Reader System (Cellular Technology, Shaker Heights, OH, USA).
Pneumococcal challenge
At week 10, mice were challenged by intraperitoneal injection
with 1610
4 CFU of S. pneumoniae WU2 in 100 ml BSG [5]. The
50% lethal dose (LD50)o fS. pneumoniae WU2 in BALB/c mice was
1610
2 CFU. Challenged mice were monitored daily for 15 days.
Statistical analysis
Numerical data are presented as arithmetic means for bacterial
number data and geometric mean and standard deviation in all
other assays. Mann-Whitney U Test (version 5.0; GraphPad
Software, Inc.) was used for comparing the distribution of S. Typhi
in tissues of newborn mice, survival of S. Typhi strains in
peripheral human mononuclear cells, in human blood, chlorinated
tap water, raw sewage and surface water. An ANOVA (SPSS
Software) analysis, followed by LSD (Least Significant Difference)
method, was used to evaluate differences in antibody titer and
cytokine-secreting cells response discerned to 95% confidence
intervals. The Kaplan-Meier method (SPSS Software) was applied
to obtain the survival fractions following i.p. challenge of
intranasally immunized mice. P,0.05 was considered statistically
significant.
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Vaccine construction and characterization
The mutations introduced into each of the parent strains, S.
Typhi Ty2 and S. Typhi ISP1820, were based on several strategies
including regulated-delayed in vivo attenuation [28] and regulated
delayed in vivo antigen synthesis [30] worked out in S.
Typhimurium and are comparable to the mutations in S.
Typhimurium UK-1 strain x9558 [34,35,37]. The mutations
introduced into both parental strains, S. Typhi Ty2 and S. Typhi
ISP1820, were DPcrp527::TT araC PBAD crp, DPfur81::TT araC PBAD
fur, Dpmi-2426, D(gmd-fcl)-26, DrelA198::araC PBAD lacI TT,
DsopB1925, DagfBAC811, DtviABCDE10, DaraE25, and DasdA33.
As described below, the DaraBAD23 mutation was also introduced
into ISP1820 (Fig. 1). The chromosomal DNA regions flanking the
point of the deletion or insertion/deletion mutations used to
construct the relevant suicide vectors for the DPcrp527::TT araC
PBAD crp, Dpmi-2426, D(gmd-fcl)-26, DrelA198::araC PBAD lacI TT,
DsopB1925, DagfBAC811, and DaraE25 mutations were amplified
from the S. Typhimurium UK-1 chromosome. The DNA flanking
regions used for constructing the DPcrp527::TT araC PBAD crp and
DagfBAC811 mutations share 99% similarity with S. Typhi DNA
sequence. The suicide vectors flanking region used to construct
Dpmi-2426, D(gmd-fcl)-26, DrelA198::araC PBAD lacI TT,
DsopB1925, DaraE25, share 99–100%, 98%, 98–99%, 97–98%,
99, and 97–98% similarity with S. Typhi DNA sequence,
respectively. The chromosomal DNA flanking regions used to
construct the relevant suicide vectors for DPfur81::TT araC PBAD
fur, DasdA33, and D tviABCDE10 mutations were amplified from
the S. Typhi Ty2 chromosome.
All of these mutations have been previously described
[28,29,38,48], with exception of DasdA33. The DasdA33 defined
deletion mutation encompasses a 1,104 base pair deletion
including the ATG start codon but not including the TAG stop
codon. The upstream flanking regions of S. Typhi asdA gene share
only 55% similarity with S. Typhimurium. Therefore, the flanking
regions used to construct DasdA33 were amplified from the S.
Typhi Ty2 genome. Although most of these mutations have been
described, the details of construction for some of the mutations are
described here for the first time. The DPcrp527::TT araC PBAD crp,
DPfur81::TT araC PBAD fur, Dpmi-2426 and DsopB1925 mutations,
attenuate S. Typhimurium for virulence in the oral mouse model
[28,29] (and unpublished data). In the two former mutations, the
crp and fur genes are under transcriptional control of the araC PBAD
promoter. When cells are grown in broth culture in the presence of
arabinose, crp and fur are expressed. After immunization, when the
cells reach host tissues where free arabinose is not available [31],
crp and fur are no longer expressed and the cells become attenuated
[28]. As expected for DPcrp527::TT araC PBAD crp mutants, all three
RASTyV strains formed red colonies on MacConkey maltose agar
in the presence of arabinose, and white colonies in the absence of
arabinose [28]. The DPfur81::TT araC PBAD fur phenotype was
tested using CAS plates. In absence of arabinose, a yellow ring was
observed around the colony, indicating siderophore production. In
presence of arabinose, the indicative yellow ring was not observed
as expected [28]. The OMP profile showed that the iron-uptake
OMPs, repressed by Fur, were down regulated in presence of
arabinose and up regulated in absence of arabinose (data not
shown; see reference [29]). During strain construction we observed
that a DPfur33::TT araC PBAD fur S. Typhimurium mutant
synthesized too much Fur to be optimally attenuated after growth
in 0.2% arabinose [28]. We therefore replaced the DPfur33::TT
araC PBAD fur deletion/insertion with the DPfur81::TT araC PBAD
fur deletion/insertion, in which the ATG start codon of the fur
gene was changed to GTG [28]. In S. Typhimurium DPfur81::TT
araC PBAD fur strains produce less Fur than DPfur33::TT araC PBAD
fur strains [28]. Arabinose-regulated synthesis of Crp and Fur in all
three RASTyV was confirmed by western blot analysis (Fig. 2).
The phenotypes of DPphoPQ107::TT araC PBAD phoPQ in the
absence and presence of arabinose and PhoP
+ strains were tested
by 3XD plates supplemented with 50 mg/ml of 5-bromo-4-chloro-
3-indolyl-phosphate to reveal acid phosphatase activity. Comple-
mentarily, the expression of PhoP was tested by western blot (data
not shown). However, during the course of strain construction, we
observed that a DPphoPQ107::TT araC PBAD phoPQ mutant of S.
Typhimurium is only moderately immunogenic, although highly
Figure 2. Protein expression and secretion in ISP1820 derivative x9633 carrying either pYA4088 or pYA3493. (A) Synthesis of proteins
encoded by arabinose-regulated genes. Cells were grown in NB with arabinose (Lane 0) and then diluted 1:10 into fresh NB without arabinose every
3.3 generations. This process was repeated 6 times (,20 generations) (Lane 1–6). Synthesis of Crp, Fur, LacI and PspA was detected by western blot.
GroEL was used as a control. (B) Location of PspA in x9633(pYA4088) cell fractions from cells grown in the absence of arabinose and detected by
western blot. s
70 was used as a control to detect leakage of cytoplasmic contents into other fractions.
doi:10.1371/journal.pone.0011142.g002
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construct to change the level of phoP expression, similar to the
strategy we used to improve the fur construct, but none of the
changes significantly improved the immunogenicity profile [28].
Therefore, we decided against using this mutation in our S. Typhi
vaccine vectors. Rather than completely remake our three vector
strains, we replaced the DPphoPQ107 mutation with the wild-type
phoP promoter from S. Typhi ISP1820 in all strains (Table 1;
Fig. 1).
The DagfBAC811 mutation serves to reduce the bacterium’s
ability to form thin aggregative fimbriae [74] thus reducing its
ability to survive and persist in the environment [75]. The D(gmd-
fcl) deletion blocks the conversion of GDP-mannose to GDP-
fucose, preventing colanic acid production [76,77], which may
contribute to biofilm formation in vivo [78]. The DagfBAC811 and
D(gmd-fcl) mutations were confirmed by PCR using the relevant
primers shown in Table 3 (data not shown).
The S. Typhi Vi capsular polysaccharide is involved in immune
evasion and has immunosuppressive effects on the host [79]. Also,
the Vi antigen inhibits bacterial adhesion and invasion of intestinal
epithelia [80]. TviA, a key regulator of Vi antigen synthesis, also
represses expression of genes required for synthesis of flagella and
the invasion-associated type 3 secretion system through repression
of the flagellar regulators flhDC and fliZ, resulting in reduced
invasion and reduced motility [81]. We deleted tviABCDE, genes
required for the regulation and synthesis of the Vi capsule [82].
Wild-type strains with the DtviABCDE10 deletion showed an
increase in type 3 secretion when grown in LB broth (data not
shown) and all three of the final vaccine strains were resistant to
Vi-specific phage and did not agglutinate in presence of anti-Vi
antiserum. Additional advantages for using a Vi
2 strain in our
constructs is that there will be no immune interference in
individuals who have been vaccinated with Vi or Vi-conjugate
vaccines and, along with the pmi deletion, serves to remove major
surface antigens to decrease the host immune response against
Salmonella.
The DsopB1925 deletion was introduced because sopB mutations
in Salmonella reduce fluid accumulation in ligated ileal loops [32]
and enhance the host immune response against vectored antigens
[35,83]. The DaraBAD23 deletion was introduced into our S.
Typhimurium vaccine strains to preclude acid formation due to
arabinose fermentation during in vitro growth, as this leads to a
cessation of growth [28]. Although S. Typhi does not utilize
arabinose as carbon source, the araBAD sequences of S. Typhi Ty2
and S. Typhi CT18 are identical to the S. Typhimurium sequence.
The DaraBAD23 deletion was introduced into the ISP1820
derivative. No differences in arabinose utilization were detected
on either MacConkey plates containing only arabinose or on
minimal media containing arabinose as the sole carbon source,
and therefore we did not introduce the DaraBAD23 deletion into
the S. Typhi Ty2 lineage.
Prior to the introduction of the DasdA33 mutation, a functional
rpoS gene from S. Typhi ISP1820 was introduced into the S. Typhi
Ty2 derivative. The DasdA33 mutation was then introduced into
both the S. Typhi Ty2 and S. Typhi Ty2 RpoS
+ derivatives,
yielding three attenuated vaccine strains, two derived from Ty2,
x9639 and x9640 (RpoS
+), and one from ISP1820, x9633
(Table 1; Fig. 1). The presence or absence of RpoS was confirmed
by evaluating catalase activity and glycogen accumulation as
described in the Materials and Methods. All strains had the
expected phenotype: RpoS
+ strains S. Typhi x9640 and S. Typhi
x9633 were positive for catalase activity and glycogen accumu-
lation and RpoS
2 strains S. Typhi Ty2 x9639 were negative for
both phenotypes.
The API20E profiles of each of the RASTyV strains (containing
pYA4088) were compared to the non-recombinant wild-type
parents in the presence and absence of 0.2% arabinose. In the
presence of arabinose, all three vaccine strains exhibited
biochemical profiles consistent with Salmonella; API code
4104540 for x9633(pYA4088) and 4004540 for x9639(pYA4088)
and x9640(pYA4088). As expected, in the absence of arabinose,
the profile for each strain was different, 4004000 for the Ty2
derivatives x9639(pYA4088) and x9640(pYA4088) and 4104000
for the ISP1820 derivative x9639. The change in identification is
the result of the lack of fermentation of all Crp-dependent sugars
(crp is not expressed in the absence of arabinose). In the presence of
arabinose, the API results for strain x9633(pYA4088) deviated
from the wild-type S. Typhi ISP1820 in respect to a positive
reaction for ornithine decarboxylase (ODC). During the strain
construction process, the positive ODC reaction was observed
following the introduction of the DPcrp527::TT araC PBAD crp and
DPfur33::TT araC PBAD fur mutations. Neither deletion alone was
sufficient to induce this phenotype: the phenotype was only
observed when the mutations were combined and was observed in
independently-derived strains, suggesting that this was not a
spontaneous mutation elsewhere in the chromosome. However, it
is unclear how the combination of DPcrp527::TT araC PBAD crp and
DPfur33::TT araC PBAD fur could result in synthesis of a functional
ornithine decarboxylase (ODC) in S. Typhi ISP1820. While it is
possible that a functional ornithine decarboxylase gene was
introduced from S. Typhimurium through the transduction
process used in strain construction, this is unlikely, as the ODC
+
phenotype was only observed in DPcrp527::TT araC PBAD crp and
DPfur33::TT araC PBAD fur double mutants.
Type I fimbriae were synthesized in all three S. Typhi mutant
strains when they were grown statically in LB broth containing
0.05% arabinose. Type I fimbrial synthesis was not assessed in the
absence of arabinose, due to poor growth of the strains in
arabinose-free media. LPS synthesis in all three vaccine strains was
dependent of the presence of D-mannose in the media as expected
due to the Dpmi-2426 mutation (data not shown).
Regulated protein synthesis in RASTyV strains
The Asd
+ plasmid vector pYA4088 (Table 2), which comple-
ments the DasdA33 deletion, carries DNA that codes for aa 3,285
of the S. pneumoniae gene pspA [30], fused at the amino-terminal end
to the b-lactamase type 2 secretion signal that directs PspA
secretion out of the cytoplasm and into the periplasm and
supernatant [6]. Plasmid pYA4088 and the parent plasmid,
pYA3493 (Table 2) that does not carry pspA gene sequence [6],
were introduced into the three S. Typhi vaccine strains. Plasmids
pYA4088 and pYA3493 were maintained and stable in all strains
for at least 60 generations. Each strain was grown in the presence
of arabinose and then diluted into media without arabinose and
serially passaged in arabinose-free media. Samples were taken
after each passage and synthesis of proteins encoded by arabinose-
regulated genes was assessed by western blots. We obtained similar
results for all three strains. The results from strain S. Typhi
ISP1820 x9633(pYA4088) and x9633(pYA3493) are shown in
Figure 2A. As arabinose was diluted away, synthesis of Crp, Fur
and LacI decreased, but PspA synthesis increased, as expected.
To verify PspA secretion, we fractionated cells from each strain
and determined the level of PspA in each fraction. Our results
indicated that greater than 50% of the PspA-Rx1 was found in the
periplasm and supernatant for all three strains. Typical results, for
S. Typhi ISP1820 x9633(pYA4088) are shown in Figure 2B. These
results are consistent with what has been reported for S.
Typhimurium [6,30].
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We noticed during the strain construction process that the
RASTyV strains grew more slowly on bile-containing media such
as MacConkey agar than the wild-type S. Typhi. This raised the
possibility that one (or more) of the mutations introduced into the
vaccine strains negatively impacted survival in the presence of bile,
and thus the RASTyV strains might have difficulty surviving
transit through the duodenum where bile from the gall bladder is
introduced into the intestine. Therefore, we assessed survival of the
RASTyV strains in the presence of deoxycholate compared to
wild-type S. Typhi. Deoxycholate concentrations in the duodenum
range from 0–1%, and may rise as high as 4% in the gall bladder
[84]. The viability of all strains decreased as the amount of
deoxycholate increased, but the behavior of the RASTyV strains
differed depending on their parental background (Fig. 3). The S.
Typhi Ty2-derived vaccine strain, x9639(pYA4088) survived at a
significantly lower rate than the wild-type S. Typhi at all
concentrations of deoxycholate (P,0.05). The remaining RAS-
TyV strains were significantly more sensitive to deoxycholate than
the wild-type strains at most concentrations tested (P,0.05).
However, for all vaccine strains, the decrease in resistance
compared to wild-type resulted in a drop in cell numbers of less
than 10-fold, suggesting that the vaccine strains should be able to
transit the intestinal tract, but may not persist for long duration in
the intestinal contents.
RASTyV strain survival in chlorinated water, in sewage
and untreated surface water
In addition to being avirulent in the host, a live attenuated
vaccine should possess some containment features to reduce its
survival and persistence in nature to preclude vaccination of
individuals who did not elect to be vaccinated [85]. We evaluated
the survival of the RASTyV strains compared to their wild-type S.
Typhi counterparts in chlorinated water, sewage and surface
water, conditions designed to mimic the environment and to
address concerns regarding the impact of releasing live attenuated,
genetically-modified organisms into the environment. Since the
chlorine concentration in our local tap water was found to vary
significantly from day to day, we elected to mimic the chlorination
process that occurs during municipal water treatment. All S. Typhi
strains were extremely sensitive to chlorinated water experiencing
several logs of killing after a 30-minute exposure (Fig. 4A).
In sewage, the titers of the RASTyV strains dropped steadily
after one day, decreasing more than 3 logs in titer over the 10-day
period (Fig. 4B). The wild-type strains survived significantly better
than the vaccine strains (P,0.01). A similar trend was observed in
the untreated surface water. The number of viable RASTyV
bacteria decreased steadily after inoculation at a more rapid rate
than the wild-type strains (Fig. 4C). The wild-type strains survived
significantly better than the RASTyV strains (P,0.01).
Survival of RASTyV strains in human blood, peripheral
human mononuclear cells, and in guinea pig
complement
The development of rapid ex-vivo assays using human blood
and freshly elutriated peripheral blood mononuclear cells (PBMCs)
have been demonstrated as reliable tools for determining
attenuation of S. Typhi for vaccine research and development
[68,86]. 1610
6 CFU of S. Typhi was added to duplicate 1.5 ml
blood aliquots from volunteers. The numbers of all the RASTyV
strains and Ty21a dropped below the detection threshold of 10
CFU/ml within 3 h and the numbers did not increase at later time
points (Fig. 5A). In contrast, the wild-type S. Typhi ISP1820 and
Ty2 parent strains survived significantly better than their vaccine
derivatives x9633(pYA4088) and x9639(pYA4088), respectively
(P,0.01). Surprisingly, the Ty2 RpoS
+ strain x8438 survived
poorly in whole human blood. No killing was observed for any of
the strains in heat-inactivated blood samples (Fig. 5B), indicating
that the poor survival of the RASTyV strains is due to their
inability to resist the microbicidal effects of active blood
components.
An important part of Salmonella pathogenesis is the ability of the
bacterium to survive and grow in macrophages [86,87].
Therefore, we evaluated the ability of our strains to survive in
human monocyte-derived macrophages (Fig. 5C). The three
Figure 3. Sensitivity of RASTyV strains to transient deoxycholate exposure. S. Typhi strains (either RASTyV or wild-type) were diluted to a
concentration of 1610
9 CFU/ml and transiently challenged with varying concentrations of sodium deoxycholate for 2 hours at 37uC. Survival of the S.
Typhi strains following challenge was assessed by plating on LB agar + 0.2% arabinose. The Ty2-derived RASTyV strains were significantly more
sensitive than wild-type to all concentrations of deoxycholate *, all parental strains different from their vaccine derivatives, P,0.05; ** 2 of the 3
parent strains different from their vaccine derivatives.
doi:10.1371/journal.pone.0011142.g003
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ability to persist and survive in PBMCs compared to their wild-
type parents at 24 h after infection (P,0.01). The ISP1820
derivative, x9633(pYA4088) survived better than any of the other
vaccine strains, while the Ty2 derivatives, x9639(pYA4088) and
Ty21a were the most sensitive to killing.
Complement is an important blood component with bacteri-
cidal effects. We evaluated the relative sensitivities of the RASTyV
strains and their wild-type counterparts to complement. Both wild-
type and RASTyV strains were sensitive to antibody-dependent
complement killing when incubated in the presence of anti-
Salmonella O-antigen group D1 antibody (Fig. 5D). In all cases, the
vaccine strains were more sensitive to complement than their wild-
type counterparts (P,0.01). In the absence of S. Typhi-specific
antibody, the wild-type strains were completely resistant to the
effects of complement. The RASTyV strains remained sensitive to
complement-mediated killing even in the absence of opsonizing
antibody. This is consistent with the work done by R. Looney
showing that the Vi capsule blocks C3 deposition on the surface of
S. Typhi, and strains lacking Vi, such as the RASTyV strains used
in this study, are susceptible to complement killing via the
alternative (non-antibody) pathway [88].
Distribution of S. Typhi strains in tissues of newborn mice
Newborn mice (24 hours old) inoculated orally with 160.2610
9
CFU of RASTyV strains, wild-type parents or S. Typhi Ty21a
survived without any symptoms of disease. We chose to use the
oral route in these experiments to establish that our strains can
overcome host defenses (e.g. low pH of stomach, presence of
antibacterial substances in the gut) allowing it to invade the host
mucosa and reach deeper tissues (e.g. spleen and liver). The
bacterial burden in tissues of newborn mice were determined at 3
and 7 days post infection (Fig. 6). All strains were able to persist in
the intestine for 7 days, although the Ty2 derivatives did so at
significantly lower numbers than their wild-type parents (P,0.05)
(Fig. 6A). All vaccine strains were less able to persist in the liver
and spleen compared to the wild-type strains (Fig. 6B and Fig. 6C).
The ISP1820 derivative x9633(pYA4088) was present in both
tissues on day 3, but was cleared by day 7.
Antibody responses in mice after intranasal
immunization with recombinant Salmonella vaccines
Groups of seven-week-old mice were intranasally immunized
with 160.2610
9 CFU each test strain. All mice immunized with
strains expressing pspA developed anti-PspA antibodies (Fig. 7A).
Strain x9640(pYA4088) (Ty2 RpoS
+) induced significantly higher
anti-PspA IgG titers than the ISP1820 derivative x9633(pYA4088)
at all time points (P,0.05 or P,0.01), and higher than the RpoS
2
Ty2 derivative x9639(pYA4088) at 4 weeks, 6 weeks and 8 weeks
(P,0.05). Anti-PspA titers increased in all groups immunized with
strains expressing pspA after the second immunization at 6 weeks.
After this boost, anti-PspA IgG antibody titers in x9639(pYA4088)
immunized mice were significantly higher than in mice immunized
with x9633(pYA4088) (P,0.05). No anti-PspA IgG was detected
in mice immunized with BSG (data not shown).
All attenuated Salmonella strains induced significant anti-LPS
titers (Fig. 7B) as early as two weeks post inoculation. After the
second immunization, significant boosting of serum antibody
responses to LPS was observed (P,0.05 or P,0.01). Similar
results were obtained for serum IgG responses against SOMPs
(Fig. 7C).
Mucosal IgA anti-PspA responses were detected by week 2 in
mice immunized with x9639(pYA4088) (RpoS
2), but not in mice
immunized with the two RpoS
+ strains (P,0.01) (Fig. 7D). By 4
Figure 4. Survival of RASTyV strains in chlorinated tap water
and raw sewage and untreated surface water. (A) Survival of
RASTyV strains in chlorinated water. 1 ml of S. Typhi containing 1610
9
CFU was added to 19 ml of chlorinated water and viability was assessed
by spread plating various dilutions at 0, 10, 30 and 60 min. (B) Survival of
RASTyV strains in raw sewage. S. Typhi strains were inoculated into
triplicate 20 ml sewage samples to a concentration of 1610
8 CFU/ml.
Viability of the Salmonella strains was assessed on days 0, 1, 3, 7 and 10
after inoculation. (C) Survival of RASTyV strains in untreated surface
water.S. Typhi strains wereinoculatedinto triplicate20 mlwatersamples
to a concentration of 1610
8 CFU/ml. Viability of the Salmonella strains
was assessed on days 0, 1, 3, 7 and 10 after inoculation. For B and C, *, all
parental strains different from their vaccine derivatives, P,0.05; ** 2 of
the 3 parent strains different from their vaccine derivatives.
doi:10.1371/journal.pone.0011142.g004
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Statistical differences were seen between groups at each time point
and titers reached a maximum by 8 weeks, after the boost that
occurred at 6 weeks. IgA responses in mice immunized with
x9633(pYA4088) were the slowest to develop (Fig. 7D).
The serum immune response to PspA was further examined by
measuring the levels of IgG1 and IgG2a (Fig. 8). Mice immunized
with ISP1820 derivative x9633(pYA4088), developed a balanced
Th1/Th2-type response against PspA (Fig. 8A), while mice
immunized with the Ty2 derivatives initially developed a strong
Th2-type response (Fig. 8B). Boosting with the RpoS
+ strain
x9640(pYA4088) elicited a balanced Th1/Th2 response (Fig. 8C),
while mice immunized with the RpoS
2 strain x9639(pYA4088)
maintained a Th2-type response after boosting.
Antigen-specific stimulation of IL-4 or IFN-c production
To further evaluate the Th1/Th2 immune response, ELISPOT
was used to determine numbers of IFN-c (Th1-associated) and IL-
4 (Th2-associated) secreting splenocytes from immunized and
control mice in response to PspA (Fig. 9). Splenocytes from mice
immunized with the RASTyV strains carrying pYA4088 produced
very low levels of PspA-specific IFN-c secreting cells (Fig. 9A). In
contrast, splenocytes from the mice immunized with any of the
RASTyV strains carrying pYA4088 produced significantly higher
levels of PspA-specific IL-4 secreting cells than those of the empty
vector controls (P,0.05 or P,0.01) (Fig. 9B). Of note, the results
with strain x9639(pYA4088), which induced a strong IL-4
response and an undetectable IFN-c response, was consistent
with the strong Th2 response indicated by the IgG1/IgG2a
analysis (Fig. 9B).
Evaluation of protective immunity
To examine the ability of RASTyV strains expressing pspA to
protect against pneumococcal infection, mice were challenged
intraperitoneally with 1610
4 CFU of S. pneumoniae WU2 four
weeks after the boost. S. pneumoniae WU2 produces PspA that is
Figure 5. Survival of RASTyV strains in human blood, peripheral human mononuclear cells, and guinea pig complement. The
bactericidal effects of (A) active whole blood and (B) heat-treated blood were compared by incubating 1610
6 CFU of each strain in 1.5 ml normal or
heat-inactivated human whole blood. Bacterial survival was measured by spread plating at the indicated times after inoculation. **, P,0.01, for each
RASTyV compared to its wild-type parent at 18 h. (C) S. Typhi survival in peripheral human mononuclear cells at 1 h, 4 h and 24 h after inoculation
with 5610
6 CFU. **, P,0.01, for each RASTyV compared to its wild-type parent at 24 h, and significant differences between Ty21a and RASTyV are
indicated. The assay was performed in duplicate and was repeated at least 3 times using blood from different individuals. The limit of detection was
less than 10 CFU/ml. (D) S. Typhi survival in guinea pig complement three hours after inoculation with 1610
6 CFU. **, P,0.01, for the RASTyV strain
compared to its wild-type parent at 3 h. Data shown are the arithmetic means of triplicate samples.
doi:10.1371/journal.pone.0011142.g005
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immunized with RASTyV expressing pspA were significantly
protected compared with BSG and empty vector control groups
(P,0.01) (Fig. 10). The protection afforded by the Ty2 derivatives,
RpoS
+x9640(pYA4088) was significantly greater than that afford-
ed by the ISP1820 derivative x9633(pYA4088) (P,0.05).
Figure 6. Distribution of RASTyV strains in tissues of newborn mice. The numbers of Salmonella bacteria in the intestines (A), liver (B) and
spleen (C) at 3 and 7 days after oral inoculation of newborn mice with 160.2610
9 CFU of the indicated strains are plotted. Bars represent the
arithmetic mean 6 standard deviations from two separate experiments with 5 mice per group. *, P,0.05; **, P,0.01 for CFU counts in the indicated
tissues for vaccine strains compared to their wild-type parent strains. The assays were performed twice.
doi:10.1371/journal.pone.0011142.g006
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Our ultimate goal is to design an RASTyV that synthesizes
multiple pneumococcal antigens. One important often overlooked
step in that process is to identify an optimal Salmonella vector strain.
Therefore, we constructed, characterized and evaluated in mice
three recombinant attenuated S. Typhi strains derived from
ISP1820 and Ty2 (with and without a functional rpoS gene)
synthesizing one antigen, the S. pneumoniae pneumococcal surface
protein PspA, to evaluate which strain will make the best vector.
One consideration in our strain design strategy was to test our
hypothesis that immune responses induced to protective antigens
will be superior in RpoS
+ S. Typhi strains.
One of the most daunting problems encountered when
evaluating an S. Typhi vaccine is making a pre-clinical
determination of its safety and/or level of attenuation. Typically,
an identical mutation is introduced into S. Typhimurium and the
virulence of the strain is determined by oral administration to
mice. While this has proven to be an accurate first approximation,
it is clear that the interaction between S. Typhimurium and mice is
not identical to the interaction between S. Typhi and humans. In
some cases, attenuation of an S. Typhi mutant has been evaluated
by injecting low doses of the vaccine strain intraperitoneally with
hog gastric mucin into outbred mice [90]. This method has proven
reliable for demonstrating the reduced virulence of a variety of S.
Typhi strains that are attenuated by deletion or mutation of genes
that result in a growth defect, such as aro mutants [91] and Ty21a
[12]. However, the validity of this model is undermined by the
observation that a S. Typhi phoP mutant, which has no growth
defect, is just as virulent as wild-type strains [92] in this model
despite the fact that both S. Typhi and S. Typhimurium DphoPQ
mutants have been shown to be safe in Phase I clinical trials
[18,93]. In this study, we examined survival of the RASTyV
strains in whole blood, in PMBC’s and in the presence of
complement as a surrogate for safety. Our strains were exquisitely
sensitive to whole blood, with no detectable survivors after three
hours (Fig. 5A). The vaccine strains were also more susceptible
than their parent strains to killing by PBMCs (Fig. 5C), and by
guinea pig complement (Fig. 5D). The ISP1820 derivative,
x9633(pYA4088), survived better in PBMCs than either of the
Ty2 derivatives, which had similar survival curves. The survival
profiles of our vaccine strains in whole blood and PBMCs was
similar to the licensed typhoid vaccine strain Ty21a, indicating
that their attenuation phenotypes resulted in a desirable safety
profile.
Interestingly, strain x8438, the wild-type Ty2 RpoS
+ strain, had
a survival profile in whole blood that was more like the RASTyV
than wild-type Ty2. The reason for this is unclear, but it may be
related to the fact that Ty2, isolated in 1918, has, presumably,
been an rpoS mutant for many years. During that time, it is possible
that it has acquired a number of suppressor mutations that
enhanced its survival. Restoration of the mutant rpoS allele may
have led to a phenotypically less fit strain, at least with respect to
survival in blood.
This result does not appear to be related to Vi antigen
production, since both S.T y p h ix8438 (Ty2 RpoS
+)a n dS.
Typhi ISP1820 make comparable amounts of Vi, although both
Figure 7. Immune responses against PspA, S. Typhi LPS and S. Typhi OMP in immunized mice. Serum IgG responses against rPspA (A), S.
Typhi LPS (B), and S. Typhi OMP (C), and mucosal IgA responses to rPspA (D) were measured by ELISA using pooled sera and vaginal washes from
BALB/c mice intranasally immunized with the indicated strains carrying either plasmid pYA3493 (control) or pYA4088 (PspA). Mice were boosted at
week 6. ELISAs were performed twice with identical results. Significant differences were indicated *, P,0.05; **, P,0.01. No immune responses were
detected to any antigen tested in mice immunized with only BSG or in preimmune sera from vaccinated mice (reciprocal titer ,1:50).
doi:10.1371/journal.pone.0011142.g007
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these strains that may account for these observations is that S.
Typhi ISP1820 produces more LPS O-antigen than x8438
[48,82] and the production of long-chain O-antigen has been
Figure 8. Serum IgG1 and IgG2a responses to rPspA measured
by ELISA. Anti-rPspA IgG1 and IgG2a titers in pooled sera from BALB/c
mice intranasally immunized with the indicated RASTyV strains at
various times. Mice were boosted at week 6. The ratios of IgG1:IgG2a at
8 weeks were 1:1 for x9633(pYA4088) (A) and x9640(pYA4088) (C)
immunized mice respectively; and 8:1 for x9639(pYA4088) (B)
immunized mice. All ELISAs were performed twice with identical results.
doi:10.1371/journal.pone.0011142.g008
Figure 9. Antigen-specific stimulation of IFN-c (A) or IL-4 (B).
Splenectomies were performed on euthanized BALB/c mice 7 weeks
after the primary immunization and one week after the boost. Buffer
controls were also included. Splenocytes were harvested from 3 mice
per group, and cells from each spleen were assayed in triplicate. Each
symbol represents the results from a single well. The results from each
well are presented as ELISPOTS per million splenocytes minus any
background (#4) ELISPOTS, from unpulsed mock controls. There were
no significant differences between vaccine strains and the control
group for secretion of IFN-c. For secretion levels of IL-4, **, P,0.01 for
x9633(pYA4088) and x9639(pYA4088) versus controls BSG group or
empty vector group, *, P,0.05 for x9640(pYA4088) versus BSG group or
x9640(pYA3493), and for x9639(pYA4088) versus x9640(pYA4088) as
indicated.
doi:10.1371/journal.pone.0011142.g009
Salmonella Typhi Vaccines
PLoS ONE | www.plosone.org 16 June 2010 | Volume 5 | Issue 6 | e11142associated with complement resistance [94]. With regard to
environmental safety, all strains were sensitive to chlorinated
water and the RASTyV strains were less able to survive in raw
sewage compared to their wild-type parents (Fig. 4). These
results indicate that the RASTyV strains have a diminished
capacity to persist in the environment.
In day-old mice, the three RASTyV strains exhibited different
capacities for persistence of the intestinal tract. Higher numbers
of RpoS
+ strains S.T y p h ix9633(pYA4088) and S.T y p h i
x9640(pYA4088) were isolated than of RpoS
2 strain S.T y p h i
x9639(pYA4088) (Fig. 6). Although our data are limited by the
fact that we harvested the entire intestines, including contents,
these results are consistent with the observation that RpoS
regulated genes are necessary for invasion and colonization of M
cells overlying the GALT [24,26]. In spite of this shortcoming,
the data indicate that an RpoS
+ phenotype confers some
advantage in the intestinal environment. All three of the wild-
type strains were able to persist in the liver and spleen, while their
attenuated counterparts were unable to maintain detectable
numbers in these tissues. The inability of attenuated S.T y p h i
strains to persist in neonatal spleen and liver is consistent with a
previous report [95] although in that study 7-day-old mice were
inoculated intranasally. To our knowledge, this is the first report
showing persistence in day-old mice with orally administered
wild-type S. Typhi. We note that despite the ability of wild-type S.
Typhi ISP1820, Ty2, and Ty2 RpoS
+ to persist in neonatal
mouse tissues, this does not lead to a lethal infection. (Santander,
unpublished observation).
The three RASTyV strains stimulated different immune
responses to PspA. The RpoS
+ vaccine strains S.T y p h i
x9633(pYA4088) and S.T y p h ix9640(pYA4088) induced mixed
Th1- and Th2-type serum immune responses against rPspA and
induced lower titers of IgA mucosal secretions than the RpoS
2
vaccine strain S.T y p h ix9639(pYA4088). Despite the poor
induction of IFN-c and the comparatively strong induction of IL-
4, all three strains induced high levels of PspA-specific serum
antibodies (Figs. 7 and 9). Mice immunized with S.T y p h i
x9640(pYA4088) or S. Typhi x9639(pYA4088) produced the
highest titers of PspA-specific serum antibody and experienced
the highest level of protection, significantly greater than the
protection seen in mice immunized with the ISP1820 derivative
S.T y p h ix9633(pYA4088) (Fig. 10). It is not clear what the basis
of these differences is and it is difficult to make predictions
concerning which of the three strains will be the most
immunogenic in humans, but it is clear that all three RASTyV
strains are immunogenic and protective in the intranasal mouse
model.
We have designed and fully evaluated three new RASTyV
strains that include new features including regulated delayed in
vivo attenuation and regulated delayed in vivo synthesis of the
pneumococcal antigen PspA. We have demonstrated that these
strains are immunogenic in mice, are highly susceptible to killing
in human blood, and are poorly adapted for survival in the
environment. Thus, the three RASTyV strains demonstrate a
balance between a desirable safety profile and immunogenicity
and should be completely safe when used in a clinical setting. The
results from these preclinical studies pave the way for a phase 1
clinical trial, currently underway, where we are evaluating all
three strains for safety and immunogenicity to determine the best
S. Typhi vector to enable construction of an anti-pneumococcal
vaccine. The clinical trial will allow us to address the importance
of rpoS in RASTyV immunogenicity. Based on the results of the
current clinical trial and ongoing work in our laboratory, we plan
to make adjustments to the best of these three strains to further
enhance safety to allow its use in younger and/or immunocom-
promised or malnourished populations and to incorporate
additional protective pneumococcal antigens, with the goal of
inducing protective immunity against all pneumococcal serotypes.
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Figure 10. Evaluation of protective efficacy. Groups of eight 7-weekold mice were intranasally immunized twice at 6-week intervals with the
indicated strains and challenged intraperitoneally with 1610
4 CFU of S. pneumoniae WU2 4 weeks later. The experiment was performed twice. Both
experiments gave similar results, and the data have been pooled. The protection from each RASTyV strains was significantly different compared with
control groups. *, P,0.05 for survival of mice immunized with x9640(pYA4088) (Ty2 RpoS
+) compared with survival of mice immunized with
x9633(pYA4088) (ISP1820).
doi:10.1371/journal.pone.0011142.g010
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